A new paper indicates a potential correlation between being a person of color and lacking access to emerging psychedelic therapies. Researchers emphasize that these findings are not definitive.
A retrospective analysis of clinical trials conducted by the Multidisciplinary Association for Psychedelic Studies suggests that the therapeutic benefits of psilocybin and MDMA might be disproportionately inaccessible to people of color. However, authors of the report, published this week in the Journal of the American Medical Association, stress that these observations remain strictly preliminary.
Investigators analyzed demographic data from both clinical settings and private ketamine wellness centers, noting a potential pattern of racial disparity. Experts caution against drawing broad conclusions about systemic inequality, pointing out that the overwhelming whiteness of patients could merely be an isolated statistical anomaly requiring decades of further peer-reviewed funding to fully comprehend.
While early models indicate a high concentration of affluent white patients accessing guided therapy, it is entirely too soon to rule out a spontaneous, market-driven diversification.
Until more longitudinal data is collected on exactly who can afford a guided mushroom journey, medical professionals advise the public to refrain from diagnosing the burgeoning industry with structural bias. The current evidence, while intriguing, must be treated with the utmost clinical caution.